Vivani Medical's mini exenatide implant for obesity treatment shows 20% weight loss and 82% liver fat reduction in mice, awaiting Phase 1 trial in 2024.

Vivani Medical, Inc. announced promising preclinical results for its miniature exenatide implant aimed at obesity treatment. In studies with obese mice, the implant achieved a 20% weight loss and an 82% reduction in liver fat after 28 days. The FDA has cleared Vivani's Investigational New Drug Application for the implant, enabling the upcoming LIBERATE-1 Phase 1 trial expected to start in late 2024, with results anticipated in 2025.

September 04, 2024
5 Articles

Further Reading